ERBB2 and non-small cell lung carcinoma: TDXd has been granted accelerated approval by the U.S. Food and Drug administration (FDA) for treatment-refractory, unresectable HER2-mutated NSCLC, as well as for adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic therapy and have no alternative treatment options [89,90].